Premium
Rigel Pharmaceuticals Inc (RIGL)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Ms. Kamil Ali JacksonIndependent Director | -2,50k | 87,50k | Automatic Disposition | 35,00 | 10,13k | -19,80% |
| 2026-06-01 | Mr. Dean L. SchornoExec. VP & CFO | -928,00 | 15,92k | Derivative Exercise and Sale | 12,70 - 29,86 | 38,19k | - |
| 2026-06-01 | Mr. Dean L. SchornoExec. VP & CFO | 2,45k | 38,35k | Derivative Exercise and Retained Stock | 12,70 - 18,70 | 38,19k | 6,86% |
| 2026-06-01 | Mr. David A. SantosExec. VP & Chief Commercial Officer | -874,00 | 26,10k | Sale to Issuer | 29,86 | 22,07k | -3,81% |
| 2026-06-01 | Mr. Raul R. RodriguezPresident, CEO & Director | -2,42k | 72,38k | Sale to Issuer | 29,86 | 181,14k | -1,32% |
| 2026-06-01 | Dr. Lisa RojkjaerInitié | -850,00 | 25,38k | Sale to Issuer | 29,86 | 3,54k | -19,37% |
| 2026-06-01 | Mr. Raymond J. FureyExec. VP, CCO, General Counsel & Corporate Secretary | -877,00 | 26,19k | Sale to Issuer | 29,86 | 12,95k | -6,34% |
| 2026-05-26 | Ms. Kamil Ali JacksonIndependent Director | -2,50k | 72,93k | Automatic Disposition | 29,17 | 12,63k | -16,53% |
| 2026-02-20 | Dr. Walter H. MoosIndependent Director | -4,00k | 49,44k | Derivative Exercise and Sale | 24,00 - 36,36 | 10,22k | - |
| 2026-02-10 | Dr. Lisa RojkjaerInitié | -3,76k | 130,10k | Sale to Issuer | 34,62 | 2,81k | -57,18% |
| 2026-02-10 | Mr. Raul R. RodriguezPresident, CEO & Director | -7,61k | 263,35k | Sale to Issuer | 34,62 | 179,07k | -4,07% |
| 2026-02-10 | Mr. David A. SantosExec. VP & Chief Commercial Officer | -3,55k | 122,76k | Sale to Issuer | 34,62 | 21,33k | -14,26% |
| 2026-02-10 | Mr. Dean L. SchornoExec. VP & CFO | -3,55k | 122,76k | Sale to Issuer | 34,62 | 34,02k | -9,44% |
| 2026-02-10 | Mr. Raymond J. FureyExec. VP, CCO, General Counsel & Corporate Secretary | -3,55k | 122,76k | Sale to Issuer | 34,62 | 12,21k | -22,51% |
| 2026-02-02 | Mr. David A. SantosExec. VP & Chief Commercial Officer | -5,72k | 205,91k | Sale to Issuer | 36,01 | 18,30k | -23,81% |
| 2026-01-26 | Mr. Raul R. RodriguezPresident, CEO & Director | 40,00k | 1,10M | Derivative Exercise and Retained Stock | 27,40 | 172,58k | 30,17% |
| 2026-01-26 | Mr. Raul R. RodriguezPresident, CEO & Director | -40,00k | 379,47k | Derivative Exercise and Sale | 27,40 - 37,00 | 172,58k | - |
| 2026-01-26 | Mr. Raul R. RodriguezPresident, CEO & Director | -44,75k | 1,65M | Sale to Issuer | 36,01 - 37,00 | 172,58k | -20,59% |
| 2026-02-02 | Mr. Raymond J. FureyExec. VP, CCO, General Counsel & Corporate Secretary | -3,97k | 142,89k | Sale to Issuer | 36,01 | 9,18k | -30,18% |
| 2026-02-02 | Mr. Dean L. SchornoExec. VP & CFO | -5,49k | 197,62k | Sale to Issuer | 36,01 | 30,99k | -15,05% |
| 2025-12-22 | Mr. Dean L. SchornoExec. VP & CFO | 6,50k | 139,79k | Derivative Exercise and Retained Stock | 18,70 - 24,20 | 26,19k | 33,02% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
